Table 2.

Predictors* of good clinical response to adalimumab at week 12, as defined by ACR50 and good response according to EULAR criteria

Predictors	ACR50 response		Good response according to EULAR criteria
	OR (95% CI)	p Value	OR (95% CI)	p Value
Sex (male vs female)	1.77 (1.12 to 2.79)	0.014	2.24 (1.39 to 3.59)	<0.001
HAQ-DI (per unit)	0.39 (0.25 to 0.60)	<0.001	0.54 (0.35 to 0.85)	0.007
Systemic glucocorticoids (⩽10 mg/day)†	0.57 (0.35 to 0.92)	0.022	0.53 (0.32 to 0.88)	0.014
Patient’s assessment of pain (per 0–100 mm VAS unit)	1.02 (1.01 to 1.03)	0.003	1.01 (1.00 to 1.03)	0.027
C-reactive protein (per mg/dl)	1.15 (1.01 to 1.30)	0.035	–	–
Swollen joint count (0–76; ⩾5 vs <5)	2.11 (1.13 to 3.94)	0.019	–	–
⩾1 Inflamed large joint†‡	–	–	0.55 (0.34 to 0.89)	0.015
Treatment with SSZ†	–	–	3.11 (1.35 to 7.12)	0.007
Prior DMARD use (⩾2 vs <2)	–	–	1.79 (1.08 to 2.96)	0.024

*For identification of predictors of ACR50 and good responses according to EULAR criteria, the ensemble of all potential factors was investigated by logistic regression with backward elimination (selection level, 5%); †yes vs no; ‡“large joint” could include the shoulder, elbow, knee, or hip.

ACR50, American College of Rheumatology response criteria, 50% improvement; DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; HAQ-DI, Health Assessment Questionnaire Disability Index; OR, odds ratio; PsA, psoriatic arthritis; SSZ, sulfasalazine; VAS, visual analogue scale.